إلياس شلالا نقيباً لأطباء لبنان بـ٨٧٠ صوتاً.. من هو؟
انتهت الجولة الثانية من انتخابات نقابة اطباء لبنان في بيروت، بفوز الدكتور الياس جميل شلالا بمركز نقيب اطباء لبنان في بيروت ب ٨٧٠ صوتا.
وكانت الجولة الاولى التي جرت قبل الظهر اسفرت عن فوز كل من الدكاترة:
الياس شلالا، حسن بسام، هنري فاخوري، محمد حاسبيني، فيليب يونس، بسام عليق، زهير عمر، وجورج عساف كأعضاء لمجلس النقابة .
ولصندوق التأمين والاعانة: الدكتور جو الراسي ومحمد على حوماني ورفيق سلوم ونمر عز الدين.
والمجلس التأديبي: الدكتور انطوان كاشي والدكتور مؤنس كلاكش .
ولصندوق التقاعد الدكتور كريكور اجيديان والدكتور عماد صوان والدكتور علي مشيك .
وفاز بالتزكية كل من الدكتور مروان الزغبي ومحمد الموسوي لمنصب مساعد مراقب عام لصندوق التقاعد .
من هو النقيب الجديد؟
وفي ما يلي السيرة الذاتية لنقيب اطباء لبنان الجديد وفق ما وردتنا :
CURRICULUM VITAE
Elias J Chelala, MD
1 CIVILITE
Nom: Elias J Chelala
Né le 1er janvier Décembre 1960, à Ghazir, Liban
Nationalité : Libanais
Langues : Arabe, Français, Anglais, Espagnol
2 COORDONNEES
Adresse permanente dans le pays de résidence : Kfarhabab, Kesrouan, Ghazir
Adresse de travail : Hôtel Dieu de France, Service d'ophtalmologie, Beyrouth, Liban
Téléphone (s) personnel : 9619855560, 9613252553
Messagerie électronique: [email protected]
3 TITRES ET DIPLOMES
Juillet 1988 Université Saint-Joseph Beyrouth /Liban
Spécialité en Ophtalmologie
Juillet 1988 Université de Montréal Montréal/Canada
Diplôme études spécialisées en Ophtalmologie
Mars 1985
Diplôme de Médecine du Conseil Médical du Canada
Juillet 1985 FMGEMS USA
United states médical License exam
Juillet 1984 Université Saint-Joseph Beyrouth /Liban
Diplôme de docteur en Médecine
4 SCOLARITE
Collège Notre Dame de Jamhour, Jamhour, Liban (1963-1977)
Baccalauréat Français Terminale D
Baccalauréat Libanais Sciences Expérimentales
5 Stages Pratiques
Juillet 1983 Hôtel-Dieu de France Beyrouth /Liban
Stage interne de Médecine
Juillet 1983 Hôtel-Dieu de France Beyrouth /Liban
Titulaire du poste d'ophtalmologie
Juillet 1984 - Juin 1985 Hôtel-Dieu de Paris Paris/France
Stage de CES dans le Service du Pr Yves Pouliquen
Juillet 1985- Juin 1988 Université de Montréal Montréal/Canada
Résident titulaire en Ophtalmologie
Octobre 1988-Juin 1989 Hôtel-Dieu de Paris Paris/France
Diplôme de spécialité en Echographie et techniques d'investigation du segment postérieur Service du Professeur Yves Pouliquen
6 PUBLICATIONS
Articles publiés
1. Chelala E, Hoyek S, Arej N, Kattan J, Kourie HR, Baakliny J, Antoun J. Ocular and orbital side effects of ALK inhibitors: a review article. Future Oncol. 2019 Jun; 15(16):1939-1945. doi: 10.2217/fon-2018-0608. Epub 2019 May 29
2. Under-the-Flap Crosslinking and LASIK in Early Ectasia with Hyperopic Refractive Error Sylvain el-Khoury, Youssef Abdelmassih, Mazen Amro, Elias Chelala, Elias Jarade J Ophthalmol. 2018; 2018: 4342984. Published online 2018 Nov 15. doi: 10.1155/2018/4342984
3. Abi Karam Mariana, El Rayess Samir, Arej Nicolas, Farhat Rebecca, Shakal Alexandre, Samaha Ameed, Jalkh Alexandre, Hanna Najib George, Sahyoun Marwan, Chelala Elias, Azar Georges. Post traumatic pars plana vitrectomy: Indications, timing of surgery and outcomes. Lebanese Medical Journal, vol 66 no 2.
4. Jarade EF, Chelala E, Arej N, El Rami H.Inducing fibrogenesis and new interfibrillary bonds in post-laser in situ keratomileusis keratectasia. J Cataract Refract Surg. 2018 Sep;44(9):1062-1065. doi: 10.1016/j.jcrs.2018.05.028. Epub 2018 Jul 25.PMID: 30055956
5. Abdelmassih Y, El-Khoury S, Chelala E, Slim E, Cherfan CG, Jarade E. Toric ICL Implantation After Sequential Intracorneal Ring Segments Implantation and Corneal Cross-linking in Keratoconus: 2-Year Follow-up. J Refract Surg. 2017 Sep 1;33(9):610-616. doi: 10.3928/1081597X-20170621-02.
6. Chelala E, Nehme J, El Rami H, Aoun R, Dirani A, Fadlallah A, Jalkh A. EFFICACY OF INTRAVITREAL RANIBIZUMAB INJECTIONS IN THE TREATMENT OF VITREOUS HEMORRHAGE RELATED TO PROLIFERATIVE DIABETIC RETINOPATHY. Retina. 2017 May 9. doi: 10.1097/IAE.0000000000001673.
7. Jarade EF, Slim E, Cherfan C, El Rami H, Hassan T, Chelala E. Mathematical analysis of corneal remodelling after intracorneal ring surgery in keratoconus. Int J Ophthalmol. 2017 Mar 18;10(3):348-354. doi: 10.18240/ijo.2017.03.04. eCollection 2017.
8. Chelala E, Arej N, Antoun J, Kourie HR, Zaarour K, Haddad FG, Farhat F, El Karak F, Kattan J. Central Macular Thickness Monitoring after a Taxane-Based Therapy in Visually Asymptomatic Patients. Chemotherapy. 2017;62(3):199-204. doi: 10.1159/000456653. Epub 2017 Mar 29.
9. Abdelmassih Y, El-Khoury S, Dirani A, Antonios R, Fadlallah A, Cherfan CG, Chelala E, Jarade EF. Safety and Efficacy of Sequential Intracorneal Ring Segment Implantation and Cross-linking in Pediatric Keratoconus. Am J Ophthalmol. 2017 Jun;178:51-57. doi: 10.1016/j.ajo.2017.03.016. Epub 2017 Mar 22.
10. Arej N, Fadlallah A, Chelala E.Choroidal tuberculoma as a presenting sign of tuberculosis. Int Med Case Rep J. 2016 Nov 11;9:365-368. eCollection 2016.
11. Fadlallah A, Chelala E, Robinson S, Melki S. Femtosecond laser intrastromal incisions as fiducial marks for alignment of toric IOLs. Acta Ophthalmol. 2016 Nov;94(7):e673-e674. doi: 10.1111/aos.13063. Epub 2016 Apr 29.
12. El-Khoury S, Abdelmassih Y, Hamade A, Slim E, Cherfan CG, Chelala E, Bleik J, Jarade EF. Pediatric Keratoconus in a Tertiary Referral Center: Incidence, Presentation, Risk Factors, and Treatment. J Refract Surg. 2016 Aug 1;32(8):534-41. doi: 10.3928/1081597X-20160513-01.
13. Galindo J, Fadlallah A, Robinson S, Chelala E, Melki SA.Risk factors for loss of epithelial flap integrity in laser-assisted subepithelial keratectomy surgery. J Cataract Refract Surg. 2016 Apr;42(4):591-5. doi: 10.1016/j.jcrs.2016.01.039.
14. Antonios R, Dirani A, Fadlallah A, Chelala E, Hamadeh A, Jarade E. Acute Corneal Hydrops 3 Years after Intra-corneal Ring Segments and Corneal Collagen Cross-linking. Middle East Afr J Ophthalmol. 2016 Jan-Mar;23(1):156-9. doi: 10.4103/0974-9233.171826.
15. Haque M, Jabbour S, Fadlallah A, Harissi-Dagher M, Chelala E, Melki S. Integrity of Intrastromal Arcuate Keratotomies Performed by Femtosecond Laser. J Refract Surg. 2016 Jan;32(1):67-8. doi: 10.3928/1081597X-20151207-02.
16. Mansour AM, Ahmed II, Eadie B, Chelala E, Saade JS, Slade SG, Mearza AA, Parmar D, Ghabra M, Luk S, Kelly A, Kaufman SC. Iritis, glaucoma and corneal decompensation associated with BrightOcular cosmetic iris implant. Br J Ophthalmol. 2016 Aug;100(8):1098-101. doi: 10.1136/bjophthalmol-2015-307295. Epub 2015 Dec 30.
17. Fadlallah A, Chelala E, Legeais JM. Corneal Infection Therapy with Topical Bacteriophage Administration. Open Ophthalmol J. 2015 Nov 4;9:167-8. doi: 10.2174/1874364101509010167. eCollection 2015.
18. El Rami H, Chelala E, Dirani A, Fadlallah A, Fakhoury H, Cherfan C, Cherfan G, Jarade E. An Update on the Safety and Efficacy of Corneal Collagen Cross-Linking in Pediatric Keratoconus. Biomed Res Int. 2015;2015:257927. doi: 10.1155/2015/257927. Epub 2015 Sep 29. Review.
19. Fadlallah A, Mehanna C, Saragoussi JJ, Chelala E, Amari B, Legeais JM. Safety and efficacy of femtosecond laser-assisted arcuate keratotomy to treat irregular astigmatism after penetrating keratoplasty. J Cataract Refract Surg. 2015 Jun;41(6):1168-75. doi: 10.1016/j.jcrs.2014.08.046.
20. Chelala E, Saleh N, Dirani A, Fadlallah A, Baz P, Slim E, Halaby G, Bejjani R. Screening of diabetic retinopathy and maculopathy in Lebanese population using retinography and SD-OCT: The role of telemedicine. J Med Liban. 2015 Apr-Jun;63(2):59-65. French.
21. Antoun J, Slim E, El Hachem R, Chelala E, Jabbour E, Cherfan G, Jarade EF. Rate of corneal collagen crosslinking redo in private practice: risk factors and safety. J Ophthalmol. 2015;2015:690961. doi: 10.1155/2015/690961. Epub 2015 Mar 19.
22. Antonios R, Dirani A, Fadlallah A, Chelala E, Hamade A, Cherfane C, Jarade E. Safety and Visual Outcome of Visian Toric ICL Implantation after Corneal Collagen Cross-Linking in Keratoconus: Up to 2 Years of Follow-Up. J Ophthalmol. 2015;2015:514834. doi: 10.1155/2015/514834. Epub 2015 Mar 19.
23. Chelala E, El Rami H, Dirani A, Fakhoury H, Fadlallah A. Extensive superior limbic keratoconjunctivitis in Graves' disease: case report and mini-review of the literature. Clin Ophthalmol. 2015 Mar 10;9:467-8. doi: 10.2147/OPTH.S79561. eCollection 2015.
24. Chelala E, Dirani A, Fadlallah A, Slim E, Abdelmassih Y, Fakhoury H, Baz P, Bejjani R. Effect of hemodialysis on visual acuity, intraocular pressure, and macular thickness in patients with chronic kidney disease. Clin Ophthalmol. 2015 Jan 9;9:109-14. doi: 10.2147/OPTH.S74481. eCollection 2015.
25. Fadlallah A, Dirani A, Chelala E, Antonios R, Cherfan G, Jarade E. Non-topography-guided PRK combined with CXL for the correction of refractive errors in patients with early stage keratoconus. J Refract Surg. 2014 Oct;30(10):688-93. doi: 10.3928/1081597X-20140903-02.
26. Dirani A, Fadlallah A, Syed ZA, Chelala E, Khoueir Z, Cherfan G, Jarade E. Non-topography-guided photorefractive keratectomy for the correction of residual mild refractive errors after ICRS implantation and CXL in keratoconus. J Refract Surg. 2014 Apr;30(4):266-71. doi: 10.3928/1081597X-20140320-05.
27. Chelala E, Dirani A, Fadlallah A. Intravitreal anti-VEGF injection for the treatment of progressive juxtapapillary retinal capillary hemangioma: a case report and mini review of the literature. Clin Ophthalmol. 2013;7:2143-6. doi: 10.2147/OPTH.S53243. Epub 2013 Oct 31.
28. Dirani A, Chelala E, Fadlallah A, Antonios R, Cherfan G. Bilateral macular injury from a green laser pointer. Clin Ophthalmol. 2013;7:2127-30. doi: 10.2147/OPTH.S53024. Epub 2013 Oct 30.
29. Chelala E, Rami HE, Dirani A, Fadlallah A, Fakhoury O, Warrak E. Photorefractive keratectomy in patients with mild to moderate stable keratoconus: a five-year prospective follow-up study. Clin Ophthalmol. 2013;7:1923-8. doi: 10.2147/OPTH.S52281. Epub 2013 Sep 26.
30. Chelala E, Dirani A, Fadlallah A, Fahd S. The role of topical vitamin A in promoting healing in surface refractive procedures: a prospective randomized controlled study. Clin Ophthalmol. 2013;7:1913-8. doi: 10.2147/OPTH.S52280. Epub 2013 Sep 24.
31. Antoun J, Rami HE, Jabbour E, Chelala E. Sixth, seventh and tenth cranial nerve palsies associated with pseudotumor cerebri in a 13-year-old boy. J Fr Ophtalmol. 2013 Nov;36(9):e173-6. doi: 10.1016/j.jfo.2012.11.019. Epub 2013 May 31. French.
32. Khoueir Z, Haddad NM, Saad A, Chelala E, Warrak E. Traumatic flap dislocation 10 years after LASIK. Case report and literature review. J Fr Ophtalmol. 2013 Jan;36(1):82-6. doi: 10.1016/j.jfo.2012.03.004. Epub 2012 Dec 6. Review.
33. El Rami H, Chelala E, Kourié HR, Antoun J. Grade III lipemia retinalis in a 14-year-old girl. J Fr Ophtalmol. 2012 Dec;35(10):820.e1-5. doi: 10.1016/j.jfo.2012.02.011. Epub 2012 Sep 28. French.
34. Fadlallah A, Rami HE, Fahd D, Dunia I, Bejjani R, Chlela E, Waked N, Jabbour E, Fahed S. Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis. Arq Bras Oftalmol. 2012 May-Jun;75(3):178-82.
35. Fadlallah A, Fahed D, Khalil K, Dunia I, Menassa J, El Rami H, Chlela E, Fahed S. Transepithelial photorefractive keratectomy: clinical results. J Cataract Refract Surg. 2011 Oct; 37(10):1852-7. doi: 10.1016/j.jcrs.2011.04.029. Epub 2011 Aug 15.
7 MEMOIRE(S) et THESE(S)
Dysostoses cranio-faciales en Ophtalmologie, Entretiens Ophtalmologiques de Montréal
Les agressions infectieuses de la cornée. Revue de cas, Université de Montréal.
8 COMMUNICATIONS ORALES ET POSTERS
A-Oral presentations
1-Intravitreal ranibizumab for Vitreous hemorrhage in Proliferative Diabetic Retinopathy.
Ali Dirani, Ali Fadlallah, George Azar, Elias Chelala, Henri Fakhoury, Joseph Nehme, Ramzi Alameddine, Alexandre Jalkh. (SFO, may 2014)
2-Safety and visual outcome of Visian Toric ICL Implantation after corneal Collagen Cross-Linking in Keratoconus .
Ali Dirani, Ali Fadlallah, Elias Chelala, Henry Fakhoury, Hala El Rami, Rafic Antonios, Adib Hmedeh, George Cherfan, Elias Jarade. (SFO-SAFIR, may 2014)
3-Non-topoguided photorefractive keratectomy for the correction of residual mild refractive errors after intracorneal ring segments implantation and corneal collagen cross-linking in keratoconus
Ali Dirani, Ali Fadlallah, Elias Chelala, Zeba Syed, Ziad Khoueir, George Cherfan , Elias Jarade Winter ESCRS (Ljubljana- February 2014)
4-Photorefractive Keratectomy combined to Corneal Collagen Cross-linking for the correction of Refractive Errors in patients with early stage Keratoconus.
Ali Fadlallah, Ali Dirani, Ali Fadlallah, Elias Chelala, Hala El Rami, George Cherfan, Elias Jarade. (SFO-SAFIR, may 2014)
5-The role of topical vitamin A in promoting healing in surface refractive procedures: a prospective randomized controlled study
Elias Chelala, Ali Dirani, Ali Fadlallah, Sharbel Fahed
Winter ESCRS (Ljubljana – February 2014)
6- IOL Power Calculation after ICRS Surgery for the Treatment of Post-LASIK Ectasia.
Elias Jarade, Ali Dirani, Ali fadlallah, Elias Chelala, George Cherfan
ESCRS (Amesterdam - October 2013)
7- Visian Toric ICL implantation for residual refractive errors after intracorneal ring segment implantation and corneal collagen cross-linking in keratoconus.
Elias Jarade, Ali Fadlallah, Ali Dirani, Elias Chelala, Ziad Khoueir, Joelle Antoun, George Cherfan. ESCRS (Amesterdam - October 2013)
8- Photorefractive Keratectomy for the Correction of Residual Mild Refractive Errors After Intracorneal Ring Segments Implantation and Corneal Collagen Cross-linking in Keratoconus.
Ali Fadlallah, Ali Dirani, Elias Chelala, Zyba Syed, Ziad Khoueir, George Cherfan, Elias Jarade
ESCRS (Amesterdam - October 2013)
B- Posters
1-Visual rehabilitation of patients with mild to moderate keratoconus with non topo-guided photorefractive keratectomy combined corneal collagen cross-linking
Elias Chelala, Ali Dirani, Ali Fadlallah, Rafic Antonios, Georges Cherfane, Elias Jarade. European society of cataract and refractive surgery, London (September 2014)
2-Intacs ring: does it work in pediatric age group?
Elias Chelala, Ali Dirani, Ali Fadlallah, Rafic Antonios, Georges Cherfane, Carole Cherfan, Elias Jarade. European society of cataract and refractive surgery, London (September 2014)
3-Intravitreal ranibizumab for Vitreous hemorrhage in Proliferative Diabetic Retinopathy
Ali Dirani, Ali Fadlallah, George Azar, Elias Chelala, Henri Fakhoury, Joseph Nehme, Ramzi Alameddine, Alexandre Jalkh. (ARVO may 2014)
4-Three-step procedure (ISRS + CXL + NTG-PRK) for visual rehabilitation of keratoconic patients with mild to moderate refractive error .
Ali Dirani, Ali fadlallah, Elias Chelala, Zyba Syed, Ziad Khoueir, George Cherfan, Elias Jarade. (SFO-SAFIR, may 2014)
5-Safety and visual outcome of visian toric ICL implantation after corneal collagen cross-linking in keratoconus
Ali Dirani, Ali Fadlallah, Elias Chelala, Hala El Rami , George Cherfan, Elias Jarade
Winter ESCRS (Ljubljana- February 2014)
6-Safety and efficacy of INTACS intracorneal ring segment implantation to improve best corrected visual acuity in children with keratoconus
Ali Dirani, Ali Fadlallah, Elias Chelala, Rafic Antonios, Georges Cherfan, Elias Jarade.
ESCRS (Amesterdam - October 2013)
7- Combined Non-Topo-guided PRK and cross-linking for the treatment of mild to moderate Keratoconus: A two-year follow-up study
Ali Dirani, Ali Fadlallah, Elias Chelala, Rafic Antonios, Georges Cherfan, Elias Jarade.
ESCRS (Amesterdam - October 2013)
8-Safety and efficacy of INTACS intracorneal ring segment implantation to improve best corrected visuel acuity in childrens with keratoconus
Ali Fadlallah, Ali Dirani, Elias Chelala, Rafic Antonios, George Cherfan, Elias JArade. (SFO-SAFIR, may 2014)
9-Photorefractive keratectomy in patients with mild to moderate stable keratoconus : a five-year prospective follow-up study
Elias Chelala, Hala El Rami, Ali Dirani, Ali Fadlallah, Omar Fakhoury, Elias Warrak (SFO –SAFIR, may 2014)
10-Non topo-guided photorefractive keratectomy combined to corneal collagen cross-linking for the correction of refractive errors in patients with early stage keratoconus
Ali Fadlallalah, Ali Dirani, Elias Chelala, Rafic Antonios, George Cherfan, Elias Jarade
Winter ESCRS (Ljubljana- February 2014)
11-Photorefractive keratectomy in patients with mild to moderate stable keratoconus: a five year prospective follow-up study
Elias Chelala, Ali Dirani, Ali Fadlallah
Winter ESCRS (Ljubljana- February 2014)
12-Visian toric ICL implantation after intracorneal ring segments implantation and corneal collagen cross-linking in keratoconus
Ali Fadlallah, Ali Dirani, Elias Chelala, Ziad Khoueir, Joelle Antoun, George Cherfan, Elias Jarade
Winter ESCRS (Ljubljana- February 2014)
13- Safety and visual outcome of Visian Toric ICL Implantation after Corneal Cross-linking in keratoconus.
Ali Fadlallah, Ali Dirani, Elias Chelala, Hala El Rami , George Cherfan, Elias Jarade
ESCRS (Amesterdam - October 2013)
9 Fonctions Hospitalières
Mars 1991 Hôtel-Dieu de France Beyrouth /Liban
Praticien temps partiel, Service d'ophtalmologie
Juillet 2002 Hôtel-Dieu de France Beyrouth /Liban
Praticien temps plein, Service d'ophtalmologie
10 Activités d'enseignement
DCEM III Certificat d'ophtalmologie USJ
DCEM IV DCEM V Conférences d'ophtalmologie HDF
DCEM IV Certificat de thérapeutique HDF
RESIDENTS Programme de résidanat HDF
11 Comités
Décembre 2016- en cours Hôtel-Dieu de France Beyrouth /Liban
Président du conseil Médical
Juillet 1998-2005, 2008-en cours Hôtel-Dieu de France Beyrouth /Liban
Membre du conseil Médical
Juillet 1998-2000 Hôtel-Dieu de France Beyrouth /Liban
Membre de comité des stages internés
Juillet 2005-2008 Hôtel-Dieu de France Beyrouth /Liban
Membre de comité de bloc opératoire, Président
Avril 2011 Ordre des médecins Beyrouth /Liban
Membre du Conseil de discipline de l'ordre des médecins (par élections)
12 SOCIETES SAVANTES, CULTURELLES OU SCIENTIFIQUES
Président de la Société Libanaise d'ophtalmologie (2016-2018)
Membre de « European society of cataract and refractive surgery »
Membre de la Société Française d'ophtalmologie
Membre de 'American Academy of Ophthalmology'
Membre de 'international Society of Refractive Surgery'
13 COMITES de CONGRES
The 24th annual meeting of the Lebanese ophthalmological society, May 27- 28 2016, President of the meeting. President of scientific committee
The 25th annual meeting of the Lebanese ophthalmological society, May 18 – 20 2017. President of the meeting. President of scientific committee
Les Printemps de la FM- 5è édition. 10, 11 et 12 Mai 2018. Beyrouth
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
12 minutes ago
- News.com.au
Lotto's second mega jackpot is up for grabs this week after a Tasmanian man won $70m
Just two days after a Tasmanian man became a multi-millionaire in Tuesday's Oz Lotto, $50m is up for grabs in Powerball. It's the fourth biggest Powerball prize since February, when a man from Queensland won $60m. If a ticket holder takes the division one prize on Thursday night, it will take the total winnings to $120m in a single week. The fortunate Tasmanian man who claimed the entire division one prize earlier this week said he planned to retire immediately, purchase a dream home with his partner and support his family. 'Oh, this is brilliant, absolutely brilliant … I've had a (rough) couple of years,' he said. 'I am just getting back on my feet, and I still have a mortgage when everyone else (my age) is about to retire. I have been saying I will have to work until I am 70, but not now.' Powerball is Australia's biggest jackpot lottery that has seen 21 people win a total of $524m division one prize pools this year. Last year, a man from South Australia claimed the game's biggest ever individual lottery win in Australia taking home a huge $150m. The luckiest numbers drawn in Powerball are 9, 7, 17, 11, 3, 23 and 2. The least drawn numbers are 33, 31, 29, 15, 13, 26 and 8.
Yahoo
12 minutes ago
- Yahoo
Nexus Uranium Comments on Recent Uranium Market Developments
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2025) - Nexus Uranium Corp. (CSE: NEXU) (OTCQB: GIDMF) (FSE: 3H1) ("Nexus" or the "Company") is pleased to provide an update on recent uranium market developments which positively impact the underlying fundamentals for uranium exploration, development and production. Recent market developments include the US Executive Order, spot market update, Small Modular Reactor (SMR) developments, and continued AI-driven power supply agreements, all of which have resulted in an overall improvement in the underlying uranium supply-demand fundamentals. Additionally, the Company is still awaiting pending geochemical assay results from the Winter 2025 drill program at its flagship Cree East project in the Athabasca Basin. Notable Uranium Market Developments: US Executive Order: Trump's Executive Order aims to revitalize the U.S. nuclear sector and restore domestic control over the uranium fuel cycle, establishing a national energy policy, accelerating reactor deployment, and rebuilds domestic fuel supply infrastructure. Strengthening Spot Price: Uranium spot prices have bounced off of 52-week lows of ~US$62/lb, rebounding to ~US$72/lb, on the back of improving sentiment and resumed utility activity. SMR Announcements: NuScale Power secured U.S. Nuclear Regulatory Commission (NRC) approval for its 77 MW reactor, making it the first reactor to earn NRC certification. AI-Driven Power Demand: Meta's recent 20-year supply deal continues the flurry of announcements from the likes of Google and Amazon. "The supply-demand fundamentals for uranium and clean, high-efficiency, scalable nuclear power remain as robust as ever," commented Jeremy Poirier, CEO of Nexus Uranium. "The US pronouncements and NRC's first SMR certification paves the way for significant expansion of nuclear development within the United States and ultimately for Canadian uranium explorers and developers given the reliance given the significant supply deficit for domestic production. Additionally, surging demand for AI and cloud computing puts increasingly greater requirements for clean, efficient, baseload power supply as evidenced by a string of tech-nuclear partnerships including the recent partnership between Meta and Constellation Energy." US Executive Order President Trump signed four executive orders (EOs) on May 23, 2025, intended to significantly boost U.S. deployment of advanced nuclear technologies through directives such as expediting regulatory review processes, promoting nuclear energy exports, and reforming the Nuclear Regulatory Commission. These included provisions for deployment at military installations, prioritizing the development of data centres, building a fuel bank of at least 20 tons of nuclear fuel, promoting nuclear exports, expanding capacity from 100 GW in 2024 to 400 GW by 2050, expediting timelines for project review and approval, and strengthening all aspects of the domestic supply chain. Spot Pricing Update Uranium futures rose to $71.9 per pound in early June, hovering near its highest level in over three months, and extending the rebound from eighteen-month lows in March as the possibility of political support for the nuclear sector outweighed the view of ample supply. Additionally, lack of clarity on future levies on uranium imports from Canada and Kazakhstan maintained the stress on the limited domestic capacity. SMR Developments NuScale Power has won design approval from the U.S. Nuclear Regulatory Commission (NRC) for its upgraded 77 megawatt-electric (MWe) small modular reactor (SMR), marking a key moment for the U.S. nuclear energy industry. This marks the first SMR design to earn NRC certification. Overall, SMR's allow for expedited development with scalable power with the footprint of a comparably sized conventional reactor. This announcement boosts the push for reliable, low-carbon energy as demand for cleaner electricity grows. AI-Driven Power Demand Facebook parent, Meta Platforms Inc., signed a 20-year power supply deal with Constellation Energy to help meet surging demand for artificial intelligence and other computing needs. This announcement is the latest in a string of tech-nuclear partnerships, driven by the expansion of AI, which includes Amazon, Google and Microsoft both investing in small modular reactors and long-term power supply agreements to power their fast-growing artificial intelligence platforms. About Nexus Uranium Corp. Nexus Uranium Corp. is a multi-commodity development company focused on advancing the Cree East uranium project in the Athabasca Basin in addition to its precious metals portfolio that includes the Napoleon gold project in British Columbia and a package of gold claims in the Yukon. The Cree East project is one of the largest projects within the Athabasca Basin of Saskatchewan spanning 57,752 hectares (142,708 acres) and has seen over $20 million in exploration to date. The Napoleon project comprises over 1,000 hectares and prospective for multiple forms of gold mineralization, with exploration in the area dating back to the 1970s with the discovery of high-grade gold. The Yukon gold projects are comprised of almost 8,000 hectares of quartz claims prospective for high-grade gold mineralization.. The technical content of this news release has been reviewed and approved by Warren D. Robb, (BC), a Director and VP Exploration of Nexus Uranium Corp. and a Qualified Person under National Instrument 43-101. -- FOR FURTHER INFORMATION PLEASE CONTACT: Jeremy PoirierChief Executive Officerinfo@ This news release includes certain statements and information that may constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance are forward-looking statements and contain forward-looking information, including, but not limited to, any planned exploration at the Cree East Project. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this news release, including, but not limited to the assumption that the Company will be successful in finalizing its planned drill program, including retaining a contractor to complete such program. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including, but not limited to: the risk that the conditions to closing of the proposed sale of the Company's interest in the Independence Project will not be satisfied and inherent risks associated with the mining industry and the results of exploration activities and development of mineral properties, stock market volatility and capital market fluctuations, general market and industry conditions, as well as those risk factors discussed in the Company's most recently filed management's discussion & analysis. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. To view the source version of this press release, please visit
Yahoo
12 minutes ago
- Yahoo
Kohort Completes Fundraising Round Led by The Raine Group
LONDON, June 05, 2025--(BUSINESS WIRE)--Kohort Software Limited ("Kohort" or the "Company"), a leading cohort-based forecasting platform, today announced the completion of its fundraising round led by The Raine Group ("Raine"), a leading global strategic advisory and investment firm specialized in gaming, technology, media, entertainment and sports. Existing investors Eurazeo, AlbionVC and Triple Point Ventures also participated in the investment, joined by new investors Velocity Capital and Portfolio Ventures. Using advanced machine learning, Kohort's unique platform accurately predicts the future revenue and user-based growth of online services, helping management, marketers or potential investors chart a path to profitable growth. This capital raise will be used to further invest in the capabilities of the platform and allow the company to expand from its current vertical of mobile gaming into new verticals. John Salter, Partner and Co-Founder at Raine, said, "We were immediately impressed by the value that Kohort helps unlock and their proven track record in supporting sophisticated clients, which led us to both invest and partner with the team." Alongside the investment, Kohort has also entered into a commercial partnership with Raine, enabling the firm to leverage its software to provide differentiated insights across Raine's portfolio and extensive, global network of advisory clients. This access will allow Raine to provide in-depth advice around user acquisition-driven businesses including mobile gaming, real-money games, and other B2C apps. The partnership will also enable Raine's current portfolio companies and future investments to better manage user acquisition spend. "We are thrilled to receive strong support from both new and existing investors that believe in our vision and will help position us to be the leading predictive analytics partner for game developers and investment firms," said Dan Marcus CEO of Kohort. "This new strategic partnership with Raine enables us to tap into their deep network of gaming and technology clients, further expanding our presence on a global scale. We look forward to working with the team as we further expand our business and enter this new chapter of growth." John Salter added, "At Raine, we continuously look for opportunities to invest at the forefront of innovation and in support of the continued evolution of the gaming ecosystem. Our investment in Kohort underscores that commitment – capitalizing on technological developments to form bridges between key industry players that strengthen the gaming industry as a whole. It's an exciting time for the gaming industry and we're excited to continue working with Dan and Jan to deepen Kohort's connectivity and unlock future growth." Founded by Dan Marcus and Jan Pickard, Kohort provides a proprietary SaaS platform with a machine learning-based prediction model designed to support marketing and finance teams with user acquisition ("UA") strategy, scenario planning and performance forecasting. Servicing mobile gaming studios alongside private equity and venture capital investors, Kohort provides precise revenue and consumer behavior predictions to improve UA efficiency, support due diligence efforts and optimize strategic planning. About KohortKohort is a predictive analytics platform built for decision-makers in the gaming and consumer sectors. Leveraging advanced machine learning and cohort-based forecasting, Kohort helps operators, finance teams, and investors accurately predict future revenue and user growth, optimise marketing and UA strategies, and drive capital allocation decisions. Learn more at About The Raine GroupThe Raine Group is a leading global merchant bank with an integrated focus on both advisory and principal investments in the TMT sectors. Founded in 2009, Raine has advised on some of the largest and most cutting-edge transactions in the history of TMT and has leveraged that experience to be an active, strategic value-add growth investor. Headquartered in New York, Raine has offices in San Francisco, Los Angeles, London, Barcelona, Mumbai, Shanghai and Singapore. For more information, please visit View source version on Contacts Raine Press Contact press@ ORGagnier CommunicationsDan Gagnier / Lindsay BarberRaine@ (646) 569-5897 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
